HHS quickens pace of Johnson & Johnson COVID-19 vaccine candidate
The Department of Health and Human Services today it will speed the development and manufacturing of vaccines to prevent COVID-19, starting a candidate from Johnson & Johnson subsidiary Janssen Research & Development.
The agency’s Biomedical Advanced Research and Development Authority will support non-clinical studies and a Phase 1 clinical trial of Janssen’s COVID-19 investigational vaccine, Ad26 SARS-CoV-2. The Phase 1 clinical trial is set to begin no later than fall of 2020 with the goal of making a COVID-19 vaccine available for emergency use in the United States in early 2021.
Related News Articles
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…